Due to federal restrictions, American cannabis and hemp companies are just starting to do high-level research on their products. Tikva’s manufacturer is already a decade ahead, leading the world in medical cannabis innovations, and making Tikva products virtually unmatched by anything else in the United States.
Tikva is manufactured by Panaxia Pharmaceutical Industries, in current Good Manufacturing Practices (cGMP) compliant, stabilized clean room environments under stringent guidelines and regulations typically required of FDA-regulated pharmaceutical companies. Panaxia has the clinical studies and data to support their claims.
This data validating the absorption, distribution, and metabolism of Tikva products is based on Pharmacokinetic (PK) Studies performed by Panaxia in Israel. Pharmacokinetics Studies are the study of how drugs are absorbed, distributed, metabolized, and excreted (Ratain & Plunkett, 2003). To our knowledge, no CBD brand in the United States has conducted these types of studies on their products.
In the U.S. the only testing required is a third-party test of the final product to analyze the microbial and cannabinoid composition. Tikva goes above and beyond by applying the products to the stringent quality assurance protocols required by pharmaceutical companies.
The strict quality controls begin with the hemp plant. Tikva and Panaxia reject many crops of hemp because they simply don’t meet the standard we expect. The specifications we have for raw materials surpasses current legal requirements, and few farms can deliver on these expectations.
Once a trusted and tested supply of raw materials is provided, Panaxia uses non-volatile ethanol to extract the hemp oils rich in CBD and other beneficial minor cannabinoids and terpenes. These include CBD, CBN, CBG, CBGA, and CBC, in amounts that vary based on each crop.
Panaxia’s expert research team developed the Tikva formulations by applying Galenics. The science of galenical pharmacy or galenics is the conversion of raw materials into drug substances. It also deals with the purity, formulations, desired effects, safety in use, quality control, stability, and storage of the finished product (Brange, 1987). The main raw plant materials and secondary raw materials were selected to synergistically facilitate the functioning of the dominant plant actives– for Tikva products, this is CBD. Panaxia is able to specify and add standardization of up to nine components (cannabinoids) in Tikva products.
Panaxia exceeds U.S. CBD regulatory requirements by implementing stringent quality assurance protocols required of pharmaceutical medicines. Product testing is performed throughout the manufacturing process and the finished product is tested by a third-party laboratory, analyzing residual solvents, processing chemicals, and toxins, in addition to the required microbial and cannabinoid analysis. To go to market as a Tikva product, the final product must greatly exceed the standards required by federal and state laws.
An additional article we think you will like – We’re In This Together about our Tikva community.
Ratain MJ, Plunkett WK Jr. Principles of Pharmacokinetics. In: Kufe DW, Pollock RE, Weichselbaum RR, et al., editors. Holland-Frei Cancer Medicine. 6th edition. Hamilton (ON): BC Decker; 2003. Available from: https://www.ncbi.nlm.nih.gov/books/NBK12815/